Notable Runner: Acceleron Pharma Inc’s Trend Down, Especially After Today’s Weak Session

Notable Runner: Acceleron Pharma Inc's Trend Down, Especially After Today's Weak Session

The stock of Acceleron Pharma Inc (NASDAQ:XLRN) is a huge mover today! About 278,328 shares traded hands. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 18.96% since April 27, 2016 and is uptrending. It has outperformed by 13.73% the S&P500.
The move comes after 6 months negative chart setup for the $1.30 billion company. It was reported on Nov, 30 by Barchart.com. We have $33.01 PT which if reached, will make NASDAQ:XLRN worth $52.00M less.

Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on February, 23. They expect $-0.60 earnings per share, up 25.93% or $0.21 from last year’s $-0.81 per share. After $-0.55 actual earnings per share reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Out of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Acceleron Pharma has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The firm has “Overweight” rating given on Monday, June 13 by Barclays Capital. As per Thursday, September 29, the company rating was initiated by Citigroup. Oppenheimer reinitiated the shares of XLRN in a report on Monday, February 1 with “Outperform” rating. Oppenheimer initiated Acceleron Pharma Inc (NASDAQ:XLRN) rating on Friday, November 20. Oppenheimer has “Outperform” rating and $58 price target. The rating was initiated by Barclays Capital on Wednesday, April 27 with “Overweight”. FBR Capital maintained the stock with “Outperform” rating in Friday, January 15 report. Morgan Stanley initiated the shares of XLRN in a report on Thursday, August 13 with “Overweight” rating. The rating was maintained by FBR Capital on Monday, January 18 with “Outperform”. Janney Capital initiated the shares of XLRN in a report on Thursday, December 17 with “Neutral” rating.

According to Zacks Investment Research, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.49, from 1.49 in 2016Q1. The ratio dropped, as 15 funds sold all Acceleron Pharma Inc shares owned while 32 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 28.02 million shares or 2.80% less from 28.83 million shares in 2016Q1.
Geode Cap Llc accumulated 246,359 shares or 0% of the stock. Barclays Public Limited, a United Kingdom-based fund reported 41 shares. Granite Point L P has 0.22% invested in the company for 14,941 shares. The New York-based Perceptive Ltd Limited Liability Company has invested 1.42% in Acceleron Pharma Inc (NASDAQ:XLRN). Adage Capital Partners Gru Limited Liability Company accumulated 287,500 shares or 0.03% of the stock. Sei accumulated 0% or 300 shares. Prtn Ltd Liability Company accumulated 0.14% or 52,101 shares. The Massachusetts-based Winslow Evans Crocker Incorporated has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). The Netherlands-based Alpinvest Ptnrs Bv has invested 0.63% in Acceleron Pharma Inc (NASDAQ:XLRN). Qvt Financial Limited Partnership holds 1.64% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 702,410 shares. Credit Suisse Ag, a Switzerland-based fund reported 389,653 shares. Highland Cap Lp, a Texas-based fund reported 46,863 shares. Hbk Ltd Partnership has 0.01% invested in the company for 19,184 shares. Tfs Llc reported 57,148 shares or 0.36% of all its holdings. Blackrock Ltd Liability has invested 0.02% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN).

Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 9 insider sales for $58.34 million net activity. Shares for $1.12M were sold by Ertel Steven D. The insider MCLAUGHLIN KEVIN F sold $876,898. 52,486 shares were sold by Kumar Ravindra, worth $1.78 million. George Jean also sold $30.43 million worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares. On Wednesday, September 21 the insider Quisel John D sold $1.75 million. $903,143 worth of shares were sold by Sherman Matthew L on Friday, July 1. Knopf John L had sold 100,000 shares worth $3.39 million on Friday, July 1.

More recent Acceleron Pharma Inc (NASDAQ:XLRN) news were published by: Businesswire.com which released: “Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented …” on November 30, 2016. Also Marketwatch.com published the news titled: “Plus the latest data from Realtor.com on 21 home markets across the US” on September 19, 2013. Marketwatch.com‘s news article titled: “Acceleron Pharma tabs Bayer exec as next CEO” with publication date: September 27, 2016 was also an interesting one.

XLRN Company Profile

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. The Firm focuses on discovering and developing therapeutic candidates that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment